Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (3731)	6/26/1998 8:49:00 AM
From: BigKNY3	Read Replies (1) \| Respond to of 9523

Merck leads drug group's advance amid market rally Shares of most major U.S. drug makers, led by Merck & Co advanced Wednesday amid a broad rally on Wall Street and expectations of solid second-quarter earnings for the pharmaceuticals sector, analysts said. "People are rotating into the drug group in general ahead of release of second-quarter earnings reports next month," said Merrill Lynch analyst Steve Tighe. "And when you see such a rotation, Merck tends to benefit because it's a liquid name with a low price-to-earnings ratio relative to its peers," Tighe added, referring to its P/E of about 30 compared with a group average of 37.

To: BigKNY3 who wrote (3731)	6/26/1998 11:43:00 AM
From: Barron Von Hymen	Read Replies (2) \| Respond to of 9523

Business Week article is B.S. How could they expect new prescriptions to keep increasing? There are only a finite number of men in the U.S.! The figure to watch are refills, even if the rate of sales growth slows, they are still making sales as each day goes on. That's not a good enough reason to cut 150 million in earnings of Viagra! They know European sales will add a nice chunk, totally illogical! At least BW acknowledges that once Europe sales start, new scripts should rise again.